The Therapy with Oral Anticoagulants in Patients with Atrial Fibrillation in Outpatient and Hospital Settings (Data from RECVASA Registries)

Loukianov, М. М.; Martsevich, S. Yu.; Drapkina, О. М.; Yаkushin, S. S.; Vorobyev, A. N.; Переверзева, К. Г.; Zagrebelnyy, A. V.; Yakusevich, V. V.; Yakusevich, V. V.; Pozdnyakova, Elena; Гомова, Т. А.; Fedotova, E. E.; Valiakhmetov, M. N.; Михин, В. П.; Maslennikova, Yu. V.; Andreenkо, E. Yu.; Klyashtorny, V. G.; Kudryashov, E. V.; Okshina, Е. Yu.; Panagopulu, M. A.; Boytsov, S. А.

doi:10.20996/1819-6446-2019-15-4-538-545

Cited by 13 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Источником данных, на основании которых при моделировании оценивался экономический ущерб в РФ, обусловленный смертностью, затратами на госпитализации и медикаментозное лечение больных с ХСН, были сведения, полученные из медицинских регистров РЕКВАЗА (Рязань), РЕКВАЗА ФП -Курск, РЕКВАЗА ФП -Москва, РЕКВАЗА ФП -Ярославль, РЕГИОН-ПО (Рязань), РЕГИОН-ЛД (Рязань), РЕГИОН-Москва и РЕГАТА (Рязань). Подробнее данные регистры были описаны в ранее опубликованных исследованиях [9][10][11][12][13][14]. Из этих проспективных регистров были извлечены сведения за все время наблюдения о числе госпитализаций, случаях смерти, назначаемой лекарственной терапии было основано на том, что наличие IV ФК ХСН соответствует III-IV степени выраженности стойких нарушений функций организма человека в соответствии с количественной системой оценки, предусмотренной приложением к "Классификациям и критериям", используемым при осуществлении медико-социальной экспертизы граждан федеральными государственными учреждениями медико-социальной экспертизы, т.е.…”

Section: материал и методыunclassified

Socio-economic impact of heart failure in Russia

et al. 2021

Self Cite

View full text Add to dashboard Cite

Heart failure (HF) significantly worsens the patient quality of life and leads to the disability of their significant part, as well as increases the risk of death, which in turn causes economic damage.Aim. To assess the annual socio-economic impact of HF in Russia.Material and methods. To assess the socio-economic impact of HF, a model was developed, which assessed the number of HF patients seeking medical care (data from the epidemiological studies), the number of those with disabilities and the mortality rate among them. We also evaluated the costs of drug therapy (data from the government procurement reports) and hospitalization (data from the compulsory health insurance tariffs), social benefits due to disability, and death impact on the gross domestic product. Data on the prescription rate, hospitalizations and mortality was obtained from Russian registries of patients with cardiovascular diseases. Using the foreign study, the costs of family caregiving were also calculated.Results. According to modeling data, there are 7,1 million people with HF seeking medical care in Russia. In this case, the annual economic impact of HF in the context of government spending, is RUB 81,86 billion, including medical costs of RUB 18,6 billion, direct nonmedical costs of RUB 47,1 billion, and indirect costs of RUB 16,2 billion. The impact of family caregiving is RUB 72,4 billion. In the structure of medical expenses, 73,6% is hospitalization costs, while the main costs of drug therapy are borne by patients, since only a part of them (19,6%) receive the necessary medications within assistance programs. In patients with HF with reduced ejection fraction, medical costs are 56% higher than in patients with HF with preserved ejection fraction.Conclusion. HF causes significant economic burden to the state. Improving the healthcare system for this category of patients, including preferential drug provision, will reduce HF-related mortality, the healthcare system costs and, accordingly, reduce the economic impact on the state and society.

show abstract

Section: материал и методыunclassified

Socio-economic impact of heart failure in Russia

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Анализ догоспитальной фармакотерапии у больных ИБС показал по данным регистра РЕКОРД-3 (РЕгистр острых КОРонарных синДромов), что регулярно статины принимали 24%, антиагреганты -48,6%, что также сопоставимо с полученными данными и значимо ниже показателей Европейского пилотного регист ра хронической ИБС и исследования EUROASPIRE V (European Action on Secondary and Primary Prevention by Intervention to Reduce Events), выполненном в 27 странах Европы -88,3% больных ИБС принимали антиагреганты и 84% -статины [16,17]. Частота назначения антикоагулянтов при ФП была сходной с показателями, полученными в ряде российских регистров: в регистре РЕГИОН (РЕГИстр больных, перенесших Острое Нарушение мозгового кровообращения) -20,7%; в регистрах РЕКВАЗА -16% на амбулаторном этапе и 40,2% на госпитальном этапе [18,19], в то время как по показателям ряда международных регист ров частота назначения антикоагулянтов при ФП в странах Западной Европы была значительно выше (60-80%) [20].…”

Section: таблицаunclassified

Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register)

Андреенко

Лукьянов

Якушин

et al. 2019

Cardiovasc Ther Prev

Self Cite

View full text Add to dashboard Cite

Aim. To assess age and gender characteristics and determine comorbidity, medication, and outcomes in young ambulatory patients with cardiovascular diseases (CVD) within the framework of an ambulatory prospective registry. Material and methods. The study included 3690 patients with hypertension (HTN), coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and combinations thereof, which applied to 3 Ryazan hospitals. Younger CVD patients (criterion 1-the age of 18-49 years, criterion 2-the age of men 18-54 years old and women 18-64 years old) were compared with older representatives. The presence of CVD and comorbidities, medication, and outcomes over 6 year follow-up were analyzed. Results. The age groups of 18-49 years old and ≥50 years old included 347 (9,4%) and 3343 (90,6%) patients, respectively (men-144 (41,5%) and 902 (27,0%), p<0,0001). According to criterion 2, 1369 (37,1%) people were assigned to the group of young CVD patients (men <55 years old-254 (18,6%) and women <65 years old-1115 (81,4%)). The older group included 2321 people (men-792 (34,1%) and women-1529 (65,9%)). In younger CVD patients (by criteria 1 and 2), the proportion of people with CAD, HF, AF, history of myocardial infarction (MI) and/or stroke, diabetes, respiratory and digestive diseases were significantly lower (p<0,001); there was also a lower proportion of people with cardiovascular multimorbidity. According to criterion 1, the proportion of younger people with ≥2 CVDs was 41%; according to criterion 2-62% (p<0,0001). Among patients <50 years of age, AF and stroke occurred in less than 5% of cases; MI was observed only in men. When using criteria 1 and 2 in patients with early CVD development compared with older patients, there was a larger proportion of obesity cases-19,3% and 20,2% vs 13,8% and 10,8%, respectively (p=0,002 and p=0,019) and according to criterion 2, anemia cases-10,2% and 7,1%, respectively (p=0,004). In younger patients, there were higher proportion of adequate medication-70,9% and 68,8% vs 58,5% and 64,6% (p<0,001), lower mortality-9,8% and 10,4% vs 30,8% and 39,7% (p<0,001). However, reinfarction incidence in men <50 years old was higher-22,7% vs 12,4% (p=0,04). Conclusion. In younger CVD patients compared with older patients, in accordance with criteria 1, there was a large proportion of men; in accordance with criteria 1 and 2-lower incidence of CVD and noncardiac diseases, with the exception of obesity and anemia cases (only by criterion 2). Criterion 1 is more applicable for HTN, CAD, and CHF, while criterion 2-for AF, stroke, and myocardial infarction. Younger CVD patients according to both criteria were characterized by a higher proportion of adequate medication, as well as lower mortality, the incidence of non-fatal stroke and CVD hospitalization. Men with MI history at the age of <50 years have higher reinfarction risk. CVD patients at the age of <50 years old are the target group for the prevention of cardiovascular multimorbidity and its progression.

show abstract

“…Важно, что эти исследования проводятся в регионах с высокой сердечно-сосудистой смертностью, к которым относится Ярославская область. Результаты регистров РЕКВАЗА, посвященные ФП и сочетанию этого нарушения ритма сердца с другими ССЗ, регулярно публикуются [15][16][17][18][19][20].…”

Section: Introductionunclassified

Patients with atrial fibrillation in outpatient practice: clinical characteristics and outcomes over a 10-year observation period (data from the REQUAZA AF registrу — Yaroslavl)

Yakusevich,

Martsevich

et al. 2023

Racionalʹnaâ farmakoterapiâ v kardiologii

Self Cite

View full text Add to dashboard Cite

Aim. To present clinical characteristics and assess serious adverse outcomes (death, acute cardiovascular events) in outpatients with atrial fibrillation (AF) in one of the Yaroslavl clinics for 10 years.Material and methods. A total of 212 patients with AF aged from 23 to 94 years were included in the REQUAZA AF registrу — Yaroslavl at the first visit to the clinic in 2013. Their health status was monitored over 10,5 years through in-person visits, phone contacts with patients, their relatives, and treating physicians. Recorded data included the AF type, comorbid conditions, extent and quality of examinations and treatments, development of serious adverse events, and mortality. Statistical processing was carried out using the Microsoft Office 365 application software package.Results. Most patients (66,5%) were diagnosed with persistent AF. Paroxysmal, persistent, and newly detected forms were observed in 26,4%, 3,8%, and 3,3% of patients, respectively. Most AF patients had concomitant cardiovascular diseases, most frequently hypertension (96,7%), heart failure (91,6%), and coronary artery disease (91,2%). A total of 54 patients (25,5%) had prior stroke or transient ischemic attack. Complete information was obtained for 203 patients (95,8%), of which 164 (78,5%) passed away during the follow-up period. The leading death cause was cardiovascular disease, particularly cerebrovascular events (n=111; 67,7%). The highest mortality was recorded within the first two years of follow-up, during which more than a quarter (25,1%) of the registered patients had died. The COVID-19 pandemic did not significantly affect the mortality rates. The most common AF complications were stroke and transient ischemic attack, with a total of 74 episodes in the history and follow-up period, including 7 recurrences.Conclusion. Ambulatory AF patients represent a group with a high frequency of cardiovascular events and fatal outcomes. In the observed group of ambulatory AF patients, annual mortality exceeded 10%, and over 3/4 of patients died within 10 years. The leading death cause was cardiovascular disease, primarily cerebrovascular events.

show abstract

The Therapy with Oral Anticoagulants in Patients with Atrial Fibrillation in Outpatient and Hospital Settings (Data from RECVASA Registries)

Cited by 13 publications

References 22 publications

Socio-economic impact of heart failure in Russia

Socio-economic impact of heart failure in Russia

Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register)

Patients with atrial fibrillation in outpatient practice: clinical characteristics and outcomes over a 10-year observation period (data from the REQUAZA AF registrу — Yaroslavl)

Contact Info

Product

Resources

About